XPERT ALLIANCE RENTSCHLER & VETTER SUBSTANCE PRODUCT PATIENT
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

XPERT ALLIANCE RENTSCHLER & VETTER SUBSTANCE PRODUCT PATIENT Trademark

Serial Number: 79362259 • Registration: 7334071

XPERT ALLIANCE RENTSCHLER & VETTER SUBSTANCE PRODUCT PATIENT is a trademark filed by VETTER PHARMA-FERTIGUNG GMBH & CO. KG on May 23, 2022. The trademark is classified under Class 39 (Transportation & Storage), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

VETTER PHARMA-FERTIGUNG GMBH & CO. KG (15 trademarks)

2 SCHÜTZENSTR. 87 88212
RAVENSBURG , DE

Entity Type: 03

Rentschler Biopharma SE (4 trademarks)

Erwin-Rentschler-Str. 21

Entity Type: 99

Trademark Details

Filing Date

May 23, 2022

Registration Date

March 26, 2024

Published for Opposition

January 9, 2024

Goods & Services

Medical services; medical assistance; animal healthcare services, namely, animal breeding, animal grooming, medical analysis services for diagnostic and treatment purposes; consultancy and information services relating to biopharmaceutical products, namely, providing medical information and pharmaceutical consultation in the nature of a medical consultation relating to biopharmaceutical products

Scientific and technological services, namely, scientific research, analysis, testing and development in the field of biomanufacturing and in the pharmaceutical field and research and design relating thereto; industrial analysis and research services, namely, chemical, biochemical, biological and bacteriological research and analysis and industrial research in the field of pharmaceuticals; chemistry services, namely, chemistry consultation, research in the fields of chemistry; biochemical services, namely, biochemistry consultation, research in the fields of biochemistry; services of medical, bacteriological and chemical laboratories, namely, laboratory research and laboratory analysis; research on the subject of pharmaceuticals; biochemistry research services; development of pharmaceutical, veterinary and diagnostic products and substances and methods for the manufacture thereof, in particular using biotechnological and genetically-engineered means, in the nature of research in the field of manufacturing machinery for pharmaceutical, veterinary and diagnostic products and substances, design and development of computer hardware for the pharmaceutical, veterinary and diagnostic products and substances manufacturing industries; technological consultancy relating to pharmacy, namely, consulting services in the field of pharmaceutical research and development, technical consulting in the field of pharmaceutical studies; technological consultancy in the veterinary research field; technological consultancy in the field of diagnostics, namely, consulting services in the field of pharmaceutical research and development, consulting services in the field of pharmacogenetics; quality control for others; providing information and data relating to medical research and development; development of syringes and instruments for injections, injectors and packaging for the aforesaid goods for others; product quality and product safety testing, namely, chemical testing, physical testing and process engineering testing, in particular laboratory testing; pharmacological and microbiological development, research and analysis for others; conducting clinical tests, namely, scientific research in the nature of conducting clinical trials for others; conducting technical project studies in the nature of scientific feasibility studies and technological support services being technological research in the field of pharmaceutical agent manufacturing processes and pharmaceutical co-filling and packaging processes; industrial manufacturing process development consultancy

Contract manufacturing in the field of pharmaceuticals and pharmaceutical substances; custom manufacture of veterinary preparations and substances; custom manufacture of diagnostic preparations and substances for medical and veterinary use; custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; consultancy services relating to custom manufacturing process services; assembly of products for others, custom manufacture and assembly services, custom assembly for others of electronic components for medical devices and apparatus, semiconductor components and circuit switches; consultancy and information for the customised manufacture and production processes for electronic components, semi-conductor components and circuits for medical apparatus and equipment

Bottling services and storage of goods in the nature of liquid and solid substances, especially, pharmaceuticals, medicines and solutions, for others

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Dec 18, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 23, 2024 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Oct 8, 2024 XXSS
GENERIC MADRID TRANSACTION CREATED
Oct 8, 2024 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 27, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 26, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 26, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 9, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 9, 2024 PUBO
NOTIFICATION PROCESSED BY IB
Jan 8, 2024 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 20, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 20, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 20, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 5, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 5, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 5, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 5, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 5, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 9, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 9, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 9, 2023 TROA
REFUSAL PROCESSED BY IB
Jun 7, 2023 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 12, 2023 RFCS
REFUSAL PROCESSED BY MPU
May 11, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 22, 2023 RFCR
NON-FINAL ACTION WRITTEN
Mar 21, 2023 CNRT
ASSIGNED TO EXAMINER
Mar 11, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 14, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 10, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 9, 2023 REPR